1. Home
  2. RYI vs MLYS Comparison

RYI vs MLYS Comparison

Compare RYI & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ryerson Holding Corporation

RYI

Ryerson Holding Corporation

HOLD

Current Price

$26.19

Market Cap

843.2M

Sector

Industrials

ML Signal

HOLD

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$37.39

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RYI
MLYS
Founded
1842
2019
Country
United States
United States
Employees
4200
N/A
Industry
Metal Fabrications
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
843.2M
3.1B
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
RYI
MLYS
Price
$26.19
$37.39
Analyst Decision
Hold
Strong Buy
Analyst Count
1
7
Target Price
$25.00
$47.33
AVG Volume (30 Days)
362.8K
1.5M
Earning Date
10-28-2025
02-11-2026
Dividend Yield
2.86%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$4,473,900,000.00
N/A
Revenue This Year
$0.38
N/A
Revenue Next Year
$4.72
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$17.18
$8.24
52 Week High
$27.41
$47.65

Technical Indicators

Market Signals
Indicator
RYI
MLYS
Relative Strength Index (RSI) 65.91 44.26
Support Level $23.57 $36.01
Resistance Level $26.72 $38.23
Average True Range (ATR) 0.94 1.77
MACD 0.18 0.07
Stochastic Oscillator 85.90 42.59

Price Performance

Historical Comparison
RYI
MLYS

About RYI Ryerson Holding Corporation

Ryerson Holding Corp provides a metals service center, and value-added processor and is a distributor of industrial metals with operations in the United States, Canada, and Mexico. In addition to its North American operations, it conducts processing and distribution operations in China. Its customers range from local, independently owned fabricators and machine shops to large, international original equipment manufacturers. It carries a full line of products in stainless steel, aluminum, carbon steel, and alloy steels and a limited line of nickel and red metals in various shapes and forms. The company generates substantially all of its revenue from sales of metal products. Geographically, the majority revenue is generated from the United States.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Share on Social Networks: